Compare GAME & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | AYTU |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 25.7M |
| IPO Year | 2024 | 2015 |
| Metric | GAME | AYTU |
|---|---|---|
| Price | $0.42 | $2.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 8.6M | 39.9K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | $27,632,080.00 |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.24 | $0.98 |
| 52 Week High | $2.87 | $3.07 |
| Indicator | GAME | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 74.16 | 52.34 |
| Support Level | $0.40 | $2.46 |
| Resistance Level | $0.48 | $2.66 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 78.45 | 50.87 |
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.